Related Experiment Video
Updated: Jun 10, 2025
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer
Mohamed S Othman1, Mohamed Tharwat Elabbasy2, Ahmed M Aref3
1Department of Biochemistry, College of Medicine, University of Ha'il, Ha'il, Saudi Arabia.
Abstract:
Purpose: Resistance to Trastuzumab is a significant challenge in the management of HER2-positive Metastatic Breast cancer (HER2-MBC), and a better understanding of the molecular causes of resistance is required to develop more effective treatment plans. While elevated plasma levels of miR-200 and FOXP3 have been linked to breast cancer progression and treatment response, no clinical studies have confirmed these results. Methods: The study involved 40 patients with HER2-positive metastatic breast cancer (HER2-MBC). The expression levels of miR-200c-3p and the FOXP3 gene were assessed in plasma samples at two time points: baseline (BL) and after the consent completion of one cycle of Trastuzumab, utilizing quantitative polymerase chain reaction (qPCR). Clinical response to Trastuzumab was evaluated 12 months post-therapy and correlated with the time to progression (TTP) through Kaplan-Meier analysis. Results: Low plasma expression level of miR-200c-3p was detected before therapy in HER2-MBC, compared to healthy controls, and decreased dramatically in the follow-up sample at disease progression, while increased after one cycle of Trastuzumab therapy in patients who were sensitive to Trastuzumab. At baseline, a low expression level of miR-200c was significantly associated with overexpression of FOXP3, poor prognosis, and shorter time to progression. Conclusions: The findings suggest that miR-200c-3p may be a promising biomarker for predicting the response to Trastuzumab in HER2-MBC patients.
Insights
Low plasma miR-200c-3p levels predict poor response to Trastuzumab in HER2-positive metastatic breast cancer (HER2-MBC). This biomarker, associated with FOXP3, may improve treatment strategies for HER2-MBC patients.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Trastuzumab resistance is a major hurdle in treating HER2-positive metastatic breast cancer (HER2-MBC).
- Understanding molecular resistance mechanisms is crucial for developing better treatment plans.
- Previous studies linked miR-200 and FOXP3 to breast cancer progression, but clinical validation was lacking.
Purpose of the Study:
- To investigate the clinical significance of plasma miR-200c-3p and FOXP3 expression in HER2-MBC patients.
- To determine if these markers can predict response to Trastuzumab therapy.
- To correlate biomarker levels with prognosis and time to progression.
Main Methods:
- Quantitative polymerase chain reaction (qPCR) was used to measure miR-200c-3p and FOXP3 gene expression in plasma from 40 HER2-MBC patients.
- Samples were collected at baseline and after one cycle of Trastuzumab.
- Clinical response and time to progression (TTP) were assessed and analyzed using Kaplan-Meier methods.
Main Results:
- HER2-MBC patients showed lower baseline plasma miR-200c-3p than healthy controls.
- Low baseline miR-200c-3p correlated with high FOXP3 expression, poor prognosis, and shorter TTP.
- Sensitive patients showed increased miR-200c-3p after Trastuzumab, while resistant patients showed decreased levels.
Conclusions:
- Plasma miR-200c-3p is a potential predictive biomarker for Trastuzumab response in HER2-MBC.
- Combined assessment with FOXP3 may offer insights into treatment resistance.
- These findings could guide personalized treatment strategies for HER2-MBC.
